Hosted on MSN
Novo Nordisk and Hims & Hers Health resolve patent dispute and collaborate on weight loss medications
Novo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...
Insider Monkey
Hims & Hers (HIMS) Sees Analyst Optimism Following Novo Resolution
Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 11 Best Day Trading Stocks to Buy Now. Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)’s shares on March 11th. It raised the ...
Seeking Alpha
Hims & Hers: The Novo Nordisk Deal Changes Everything
The Novo Nordisk partnership legitimizes Hims & Hers’ business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution. Hims generated $2.35B revenue in 2025 (+59% YoY) ...